Every Form 4 that BIOATLA INC (BCAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.
BioAtla, Inc. (BCAB) reported that Chief Medical Officer Eric Sievers had 134 shares of common stock withheld on August 31, 2026 to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale, and he beneficially holds 11,346 shares directly after the transaction. No transactions were made under a Rule 10b5-1 trading plan.
BioAtla, Inc. (BCAB) reported that Chief Executive Officer and director Jay M. Short, Ph.D., had 259 shares of common stock withheld on August 31, 2026 to pay income tax and related withholding obligations arising from the vesting and net settlement of previously reported restricted stock units. The company states this is not a sale of shares by Dr. Short. After this tax-withholding disposition, he holds 52,035 common shares directly and additional indirect holdings through his spouse, several 2020 irrevocable gift trusts, Capia IP, LLC, and Himalaya Parent LLC, with beneficial ownership of the latter disclaimed except to the extent of his or his spouse’s pecuniary interest. No Rule 10b5-1 trading plan is reported.
BioAtla, Inc. (BCAB) reported that Chief Financial Officer Christian Vasquez had 71 shares of common stock withheld on August 31, 2026 to pay income tax obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale; the shares were withheld by the company for tax and remittance purposes. Following this tax-withholding transaction, Vasquez directly holds 10,476 shares of BioAtla common stock, including shares purchased under the company’s ESPP.
BioAtla, Inc. Chief Financial Officer Christian Vasquez reported routine tax-withholding transactions related to equity compensation, not open‑market trades. On two dates in 2026, a total of 257 shares of common stock were withheld by the company to cover income tax obligations from vesting restricted stock units.
After the most recent withholding of 82 shares at $3.93 per share, Vasquez directly owned 10,347 shares of common stock. The reported share amounts have been adjusted to reflect a 50‑for‑1 share consolidation effective on April 6, 2026.
BioAtla, Inc. director and Chief Executive Officer Jay M. Short reported routine tax-related share dispositions rather than open-market sales. On March 12, 2026 and May 31, 2026, a total of 898 shares of common stock were withheld by the company to cover income tax obligations tied to vesting restricted stock units.
After the most recent withholding of 259 shares at $3.93 per share, Short directly holds 52,294 common shares, with additional indirect holdings through entities and a spouse. Reported amounts reflect a 50-for-1 share consolidation of BioAtla common stock effective on April 6, 2026.
BioAtla, Inc. Chief Medical Officer Eric Sievers reported routine tax-related share withholdings, not open-market sales. On two dates, a total of 494 common shares were withheld by the company to satisfy income tax obligations tied to vested restricted stock units. Following the most recent withholding, Sievers directly owned 11,840 common shares. The reported amounts have been adjusted to reflect a 50-for-1 share consolidation effective on April 6, 2026.
Sievers Eric reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. reported that Chief Medical Officer Eric Sievers received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units (RSUs) at no purchase price.
The RSU vests as to 25% of the shares on March 10, 2027, then 6.25% on the last day of each May, August, November, and February, subject to his continued service through each vesting date. Following this award, Sievers directly holds 598,705 shares of Common Stock.
SHORT JAY M PHD reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. CEO and director Jay M. Short received a grant of 430,000 shares of Common Stock in the form of a time-based restricted stock unit award. The award was granted at no cash cost and is structured to vest over several years.
According to the vesting schedule, 25% of the RSU is scheduled to vest on March 11, 2027, with an additional 6.25% vesting on the last day of each May, August, November and February thereafter, subject to his continued service. Following this grant, Dr. Short directly holds 2,659,603 shares of Common Stock.
The filing also lists indirect holdings in BioAtla shares held by his spouse, various 2020 irrevocable gift trusts, Capia IP, LLC and Himalaya Parent LLC. For Himalaya Parent LLC, he and his spouse act as managers and collectively make investment decisions, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
Vasquez Christian reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. Chief Financial Officer Christian Vasquez received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units. These units carry no purchase price and increase his direct holdings to 530,196 shares after the award.
The RSU grant vests over time: 25% of the shares vest on March 10, 2027, with an additional 6.25% vesting on the last day of each May, August, November, and February thereafter, as long as he remains in service through each vesting date.
BioAtla, Inc. reported that Chief Executive Officer Jay M. Short, Ph.D., had 7,728 shares of common stock withheld on February 28, 2026 at $0.247 per share. According to the filing, this was a tax-withholding disposition related to the vesting and net settlement of previously reported restricted stock units, and not an open-market sale.
After this withholding, Dr. Short directly holds 2,229,603 common shares. He also has indirect ownership positions through his spouse and various entities, including the Carolyn Short 2020 Irrevocable Gift Trust, the Jay Short 2020 Irrevocable Gift Trust, Capia IP, LLC, and Himalaya Parent LLC, where he and his spouse serve as managers and disclaim beneficial ownership beyond any pecuniary interest.
BioAtla, Inc. Chief Financial Officer Christian Vasquez reported a tax-related share disposition, not an open-market sale. On the reported date, 1,802 shares of common stock at a value of $0.247 per share were withheld by the company to cover income tax obligations tied to vesting restricted stock units. After this withholding event, Vasquez directly owned 290,196 shares of BioAtla common stock. This type of Form 4 transaction reflects routine equity compensation tax settlement rather than discretionary trading in the open market.
BioAtla, Inc. reported an insider equity transaction involving its Former Chief Financial Officer, Richard A. Waldron. On February 28, 2026, 2,729 shares of common stock at $0.247 per share were withheld by the company to satisfy income tax obligations tied to vesting restricted stock units. This tax-withholding disposition is not an open-market sale, and Waldron’s directly held stake stands at 343,421 common shares after the transaction.
BioAtla, Inc. reported an insider equity transaction for Chief Medical Officer Eric Sievers. On this Form 4, the company withheld 3,140 shares of common stock at $0.247 per share to satisfy income tax and withholding obligations related to the vesting of previously reported restricted stock units. This withholding is characterized as a tax-withholding disposition and is explicitly noted as not being a sale of shares by the reporting person. After this transaction, Sievers directly held 358,705 shares of BioAtla common stock.